Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8317767 | 1.00 | EGLN2 (0.46) | EGLN2MMP2MAPTHTTSAE1 | |
| SCHEMBL8316645 | 1.00 | EGLN2 (0.46) | EGLN2MMP2MAPTHTTSAE1 | |
| SCHEMBL407716 | 0.80 | ALDH1A1 (0.45) | EGLN2MAPTHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28956694 | 0.80 | ALDH1A1 (0.45) | EGLN2MAPTHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7275456 | 0.80 | ABCC9 (0.44) | MMP2MAPTHTTSAE1UBA2 | |
| SCHEMBL1724786 | 0.76 | EGLN2 (0.44) | EGLN2GLAMEN1KMT2A | |
| SCHEMBL12126047 | 0.76 | MAPT (0.44) | MAPTHTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL28827422 | 0.76 | MAPT (0.41) | MAPTHTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL33651 | 0.76 | MAPT (0.41) | MAPTHTTSMN1; SMN2ALDH1A1ADRB2 | |
| SCHEMBL18412373 | 0.76 | LOXL2 (0.44) | MMP2SAE1UBA2ALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951295-B1 | COMPOSITIONS FOR USE IN INHIBITING OF ALPHA-V-BETA3 MEDIATED ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2006-11-30 | — | — | US | disclosed |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-07-27 | — | — | US | disclosed |
| US-7053041-B1 | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050143582-A1 | Method for producing substituted 3-phenylamino-propane-1,2-diols | MERCK PATENT GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1474382-A1 | METHOD FOR PRODUCING SUBSTITUTED 3-PHENYLAMINO-PROPANE-1,2-DIOLS | MERCK PATENT GmbH (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-20040063790-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2004-04-01 | — | — | US | disclosed |
| US-20030176334-A1 | Methods and compositions useful for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-09-18 | — | — | US | disclosed |
| WO-2003068730-A1 | METHOD FOR PRODUCING SUBSTITUTED 3-PHENYLAMINO-PROPANE-1,2-DIOLS | MERCK PATENT GMBH (DE) | 2003-08-21 | — | — | WO | disclosed |
| US-6602876-B1 | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| WO-1997045137-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-04 | — | — | WO | disclosed |
| US-5627197-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-05-06 | — | — | US | disclosed |
| WO-1997006791-A9 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | — | 1997-04-03 | — | — | WO | disclosed |
| WO-1997006791-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-02-27 | — | — | WO | disclosed |
| US-5561148-A | Adhesion receptor antagonists III | MERCK PATENT GESELLSCHAFT MIT BESHRANKTER HAFTUNG (DE) | 1996-10-01 | — | — | US | disclosed |
| EP-0727425-A1 | Adhesion receptor antagonists | MERCK PATENT GmbH (DE) | 1996-08-21 | — | — | EP | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0710657-A1 | Antagonists of adhesion receptors | MERCK PATENT GmbH (DE) | 1996-05-08 | — | — | EP | disclosed |
| EP-0645376-A1 | Substituted 1-phenyl-oxazolidin-2-one derivatives, their preparation and their use as adhesion-receptor antagonists | MERCK PATENT GmbH (DE) | 1995-03-29 | — | — | EP | disclosed |
| EP-0623615-A1 | Adhesion-receptor antagonists | MERCK PATENT GmbH (DE) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063790-A1 | Methods for inhibition of angiogenesis | FLT4, ANXA3, VCAM1 | EGLN2 517/4885MMP2 46/4885MAPT 4869/4885 |
| US-20030176334-A1 | Methods and compositions useful for inhibition of angiogenesis | VCAM1, FLT4, TEK | EGLN2 381/4885MMP2 94/4885MAPT 4822/4885 |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | ITGA5, ITGB5, ITGAV | EGLN2 1457/4885MMP2 359/4885MAPT 3552/4885 |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | FLT4, KDR, FLT1 | EGLN2 635/4885MMP2 18/4885MAPT 4764/4885 |
| US-20050143582-A1 | Method for producing substituted 3-phenylamino-propane-1,2-diols | HPD, PAH, DHPS | EGLN2 104/4885MMP2 3990/4885MAPT 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.